Subchronic toxicity and genotoxicity studies of Antrodia mushroom β-glucan preparation

Chen, S.N.; Chang, Chen; Chen, S.; Soni, Madhu G.

doi:10.1016/j.yrtph.2017.12.022

Cited by 9 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It have not induced any significant subchronic toxicity in rodents and was not mutagenic (Chen et al, 2011). These findings were consistent with those of subchronic toxicity and genotoxicity studies on β-glucan from Antrodia cinnamomea (Chen, Chang, Chen, & Soni, 2018). The no observable adverse effects level (NOAEL) for mushroom β-glucan was 2,000 mg/kg BW/day.…”

Section: Safety Concerns Of Macrofungus Cultivation and Consumptionsupporting

confidence: 84%

Macrofungi: A review of cultivation strategies, bioactivity, and application of mushrooms

Lou

et al. 2020

Comp Rev Food Sci Food Safe

116

View full text Add to dashboard Cite

The production of macrofungi (mushrooms) as well as their economic value have been steadily increasing globally. The use of functional foods, dietary supplements, and traditional medicines derived from macrofungi is increasing as they have numerous health benefits as well as abundant nutrients. Macrofungi are diverse with complex and highly varied growth conditions and bioactive constituents, most macrofungal resources have not yet been fully explored and applicated, leading to an urgent need for appropriate strategies to address the problem. Increasing attention has been paid to the macrofungal cultivation and application, in particular, potential prebiotics. Herein, the present review comprehensively summarizes recent progress in the cultivation, newly identified bioactive constituents, and their effects on gut microbiota as well as the potential ways in which they affect human health. Moreover, the macrofungal food development is discussed to improve food nutritional value and change the quality characteristics of food. Finally, the review addresses consumer safety concerns and the prospective genetic manipulation of macrofungi. We hope that this review can provide a comprehensive research reference for ensuring the safety and efficacy, along with maximizing the value and profitability of macrofungi production.

show abstract

Section: Safety Concerns Of Macrofungus Cultivation and Consumptionsupporting

confidence: 84%

Macrofungi: A review of cultivation strategies, bioactivity, and application of mushrooms

Lou

et al. 2020

Comp Rev Food Sci Food Safe

116

View full text Add to dashboard Cite

show abstract

“…Yeast BG at different concentrations showed no adverse inflammatory, hematological or toxicological effects in mice [74]. Several studies report the safety of oral BGs consumption regardless of the source (oat, mushroom, or yeast) or used doses [75,76].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats

Guilarducci

Marcelino

Konig

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background: The regular intake of fiber generates numerous health benefits. However, the efficacy depends on the duration of consumption and the ingested dose. Studies investigating the optimal dose are of interest to enable the inclusion of fiber in the routine treatment of diabetic patients. Objective: We aimed to evaluate the effects of different doses of β-glucan (BG-isolated from Saccharomyces cerevisiae), in comparison to n-3 supplement, on the inflammatory and metabolic parameters of Wistar rats induced to diabetes by streptozotocin. Methods: Forty animals were randomly divided into six groups receiving 0 mg/kg, 10 mg/kg, 20 mg/kg, or 40 mg/kg BG daily for 4 weeks or fish oil derivative [1000 mg/kg of omega-3 fatty acids (n-3)] for the same period. One additional group was composed of healthy controls. Serum metabolic and immunological parameters were evaluated by colorimetric and ELISA assays respectively. Histopathological analysis of the liver, small intestine and pancreas were also conducted. Significant changes due to BG intake were set into regression models with second-degree fit in order to estimate the optimal BG dose to achieve health benefits. Results: The animals that ingested BG had lower food and water intake (p < 0.05) than the negative control group (0 mg/kg). However, consumption was still elevated in comparison to healthy controls. Blood glucose and serum levels of total cholesterol, LDL-c, and TG (p < 0.05) reduced in comparison to diabetic animals without treatment (better or similar to n-3 group depending on dose), but did not reach normal levels (in comparison to healthy controls). HDL-c was not different (p > 0.05) among all groups. These reductions were already seen with the lowest dose of 10 mg/kg. On average, the serum levels of the hepatic enzymes ALT and AST were 40% and 60% lower in the BG groups in comparison to diabetic animals without treatment (better results than n-3 group). The group receiving 40 mg/kg reached similar values of healthy controls for ALT; whereas the same result occurred from the dose of 10 mg/kg for AST. The ideal dose, estimated from the mean of all metabolic parameters was approximately 30 mg/kg/day. Regarding the

show abstract

“…β-glucan (∼65% pure) from AC was analyzed in the subchronic toxicity and mutagenicity study in CD (SD) IGS rats (∼6 weeks old, 12/sex/group), and a daily dose of 2 g/kg for 3 months of oral treatment did not show any adverse effects and genotoxicity ( Chen et al, 2018 ). Therefore, AC and some of its bioactive metabolites showed no obvious toxicity within a reasonable dose range.…”

Section: Safety Evaluation Of Acmentioning

confidence: 99%

Current and further outlook on the protective potential of Antrodia camphorata against neurological disorders

Li,

Wan,

Qiao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Prevalent neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and stroke are increasingly becoming a global burden as society ages. It is well-known that degeneration and loss of neurons are the fundamental underlying processes, but there are still no effective therapies for these neurological diseases. In recent years, plenty of studies have focused on the pharmacology and feasibility of natural products as new strategies for the development of drugs that target neurological disorders. Antrodia camphorata has become one of the most promising candidates, and the crude extracts and some active metabolites of it have been reported to play various pharmacological activities to alleviate neurological symptoms at cellular and molecular levels. This review highlights the current evidence of Antrodia camphorata against neurological disorders, including safety evaluation, metabolism, blood-brain barrier penetration, neuroprotective activities, and the potential on regulating the gut-microbiome-brain axis. Furthermore, potential strategies to resolve problematic issues identified in previous studies are also discussed. We aim to provide an overview for the ongoing development and utilization of Antrodia camphorata in cerebral neuropathology.

show abstract

Subchronic toxicity and genotoxicity studies of Antrodia mushroom β-glucan preparation

Cited by 9 publications

References 24 publications

Macrofungi: A review of cultivation strategies, bioactivity, and application of mushrooms

Macrofungi: A review of cultivation strategies, bioactivity, and application of mushrooms

Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats

Current and further outlook on the protective potential of Antrodia camphorata against neurological disorders

Contact Info

Product

Resources

About